Navigation Links
Prozac Gets Conditional Clearance For Treating Children

Prozac has been cleared for treating children over eight years suffering from depression, but regulators have imposed strict conditions on its use//.

The conditions imposed by the European licensing agency (EMEA) call for the use of the drug only when other therapies have failed. "Prozac should only be used together with psychological therapy in patients non-responding to such therapy alone after four to six sessions," said the EMEA.

Also if the child does not respond in nine weeks, it should be reconsidered. Such a move has never happened before, says Tim Kendall, joint director of the National Collaborating Centre for Mental Health. "This is the first time to my knowledge that a drug has been given a license which includes a period of psychological treatment before and during the drug treatment," he said.

The Department of Health said that anti-depressants should be rarely used in children aged 5 to 11 years, but some conditions do warrant their use, "It is important to note that some drugs which may be classified as antidepressants are used for other disorders such as nocturnal enuresis (bed-wetting), anxiety, obsessive compulsive disorder and phobic states."


'"/>




Page: 1

Related medicine news :

1. Prozac miracle could end in disaster
2. Drug Prozac was found to control anger in post-stroke patients
3. Ultimate Destination of anti-depressant, Prozac
4. Prozac Unplugged
5. Prozac-popping Elders at Higher Risk of Fractures
6. Treating eye pain eases migraine
7. Treating wounds without stitches
8. Treating varicose veins
9. Treating acne with laser
10. Once-Daily Cipro(R) XR for Treating Complicated Urinary Tract Infections
11. Treating Stroke Patients in Rural Areas
Post Your Comments:
Breaking Medicine Technology:National Ergonomics Expo Sees Immediate 93% Exhibit Space Renewal for 2010; Equipois, Herman Miller, Neutral Posture, REDpoint International Win 2009 Attendees' Choice New Product Awards 2Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Baxa Corporation Releases IntelliFlowRx 28TM 29 Upgrades 49198 1Baxa Corporation Releases IntelliFlowRx 28TM 29 Upgrades 49198 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 1Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late Stage Leukaemia 12671 7Stroke Damage Is Less in Rats Given Opioids 49194 1